HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB: ARDM) (“Aradigm” or the “Company”) today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 8,119,156) covering formulations of liposomal and free ciprofloxacin, including its lead preparation, Pulmaquin™ (Dual Release Ciprofloxacin for Inhalation, DRCFI, ARD-3150). The Company expects that the patent will provide exclusivity for Pulmaquin until October 22, 2028.
